BioAge Labs Inc [BIOA] stock is trading at $5.94, down -3.26%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BIOA shares have gain 43.48% over the last week, with a monthly amount drifted -67.79%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
BioAge Labs Inc [NASDAQ: BIOA] stock has seen the most recent analyst activity on December 10, 2024, when Morgan Stanley downgraded its rating to a Underweight and also revised its price target to $5 from $40. Previously, Jefferies downgraded its rating to Hold on December 09, 2024, and dropped its price target to $7. On December 09, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $7 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $40 on October 21, 2024. Jefferies initiated its recommendation with a Buy and recommended $42 as its price target on October 21, 2024. Citigroup started tracking with a Buy rating for this stock on October 21, 2024, and assigned it a price target of $45.
BioAge Labs Inc [BIOA] stock has fluctuated between $3.85 and $26.62 over the past year. Currently, Wall Street analysts expect the stock to reach $30.67 within the next 12 months. BioAge Labs Inc [NASDAQ: BIOA] shares were valued at $5.94 at the most recent close of the market. An investor can expect a potential return of 416.33% based on the average BIOA price forecast.
Analyzing the BIOA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is 1.17 and Total Capital is -0.21. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.42 points at the first support level, and at 4.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.80, and for the 2nd resistance point, it is at 7.67.
Ratios To Look Out For
For context, BioAge Labs Inc’s Current Ratio is 17.63. Further, the Quick Ratio stands at 17.63, while the Cash Ratio is 17.53.
Transactions by insiders
Recent insider trading involved Pande Vijay Satyanand, Director, that happened on Oct 01 ’24 when 0.13 million shares were purchased. Director, Pande Vijay Satyanand completed a deal on Oct 02 ’24 to buy 67096.0 shares. Meanwhile, Director Pande Vijay Satyanand bought 25306.0 shares on Oct 03 ’24.
